Abstract
5001Background: Docetaxel has proved to prolong survival in advanced castrate resistant prostate cancer (PCa) and we therefore started this trial to evaluate if six courses of docetaxel improves bi...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
